Clinical trials: Relapsing Polychondritis
Relapsing Polychondritis
Low-dose Recombinant Human IL-2 for the Treatment of Relapsing Polychondritis
Relapsing polychondritis (RP) is a rare, systemic autoimmune disorder characterized by episodic inflammation of cartilaginous structures.
- Trial name
- NCT04077736
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking University People's Hospital
Takayasu's Arteritis, Giant Cell Arteritis
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Background: Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse.
- Conditions
- Takayasu's Arteritis, Giant Cell Arteritis, Polyarteritis Nodosa, Relapsing Polychondritis
- Trial name
- NCT02257866
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Relapsing Polychondritis
Pediatric Relapsing Polychondritis : Diagnosis and Management in a French Retrospective Study
The incidence in pediatrics is very low (about 3.5 per million per year according to a 2015 study) and therefore the data on the pathology very poor, especially on the therapeutic level.
- Trial name
- PRP (NCT06019221)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Strasbourg, France
Rheumatoid Arthritis, Ankylosing Spondylitis
PatientSpot Formerly Known as ArthritisPower
Patient Power is a patient research network and database (registry) to collect prospective information about demographics, self-reported diagnoses and medications, and willingness to participate in research from participants with…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout
- Trial name
- NCT03840928
- Where
- United States
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Global Healthy Living Foundation
Relapsing Polychondritis, Vasculitis
Longitudinal Study for Relapsing Polychondritis
Relapsing polychondritis (RP) is a rare systemic inflammatory disease characterized by recurrent inflammation of cartilage including ears, nose, tracheobronchial tree, chest wall and joints.
- Trial name
- NCT04919538
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Pennsylvania
Relapsing Polychondritis
Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab
Relapsing polychondritis (RP) is a rare, immune-mediated disease associated with inflammation in cartilaginous structures and other tissues throughout the body.
- Trial name
- NCT01041248
- Testing
- Tocilizumab
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Children's Hospital of Eastern Ontario
Giant Cell Arteritis, Takayasu Arteritis
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Vasculitis occur when the body's immune system, rather than protecting the body, attacks blood vessels, causing injury to the vessel and the part of the body it supplies with blood.
- Conditions
- Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome, Relapsing Polychondritis
- Trial name
- BIOVAS (NCT05168475)
- Testing
- Rituximab, Infliximab, Tocilizumab
- Where
- 5 sites in United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Relapsing Polychondritis
Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis
Relapsing polychondritis (RP) is a rare, systemic autoimmune disorder characterized by episodic inflammation of cartilaginous structures.
- Trial name
- NCT06873100
- Testing
- Upadacitinib, corticosteroids and immunosuppressants
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Relapsing Polychondritis
Tocilizumab for Relapsing Polychondritis
This is a study for one patient with severe relapsing polychondritis which has been unresponsive to other more conventional medications including prednisone, methotrexate, anakinra and TNF inhibitors.
- Trial name
- NCT01104480
- Testing
- Tocilizumab
- Where
- Canada
- Sponsor
- McMaster Children's Hospital
Relapsing Polychondritis
Study on the Safety of Abatacept in Relapsing Polychondritis
The purpose of this study is to test the safety of the study drug abatacept and see what effects (good and bad) it has in patients with relapsing polychondritis.
- Trial name
- NCT01272856
- Testing
- Abatacept
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Benaroya Research Institute
Physical Activity
Physical Training in Patients With Relapsing Polychondritis
Physical training may improve physical capacity and health parameters in various systemic autoimmune diseases. Therefore, the present study will assess the role of an exercise training program in patients with relapsing…
- Trial name
- NCT03092141
- Testing
- Physical training
- Where
- Brazil
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Relapsing Polychondritis
Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing Polychondritis
Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).
- Trial name
- PROSECT RP (NCT06941376)
- Testing
- Methotrexate (MTX), Azathioprine (AZA), Adalimumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania